PHASE 3B, OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE PRACTICABILITY AND TOLERABILITY OF SWITCHING SUBJECTS OVERNIGHT FROM PRAMIPEXOLE OR ROPINIROLE TO ROTIGOTINE TRANSDERMAL PATCH AND ITS EFFECT ON SYMPTOMS IN SUBJECTS WITH IDIOPATHIC RESTLESS LEGS SYNDROME
Latest Information Update: 04 Apr 2016
At a glance
- Drugs Rotigotine (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Schwarz BioSciences
Most Recent Events
- 23 Aug 2011 New trial record